Immunotherapy Resistance: Why Cancer Fights Back

Immunotherapy was supposed to change everything — and in many ways, it has. Patients with cancers once considered untreatable have gone into long-term remission. But oncologists will tell you something the press releases often don't: resistance is common, and when it happens, it can feel like the cancer has learned to cheat.

Understanding why immunotherapy fails is no longer just a question for researchers. For patients and families navigating cancer diagnosis and treatment options, it matters directly.

What Immunotherapy Actually Does

Before getting into resistance, a quick primer. Immunotherapy works by helping your own immune system recognise and attack cancer cells. The most widely used form — checkpoint inhibitors — lifts the "brakes" the cancer puts on immune cells. Drugs like pembrolizumab (Keytruda) and nivolumab essentially tell your T-cells (the immune system's attack cells) to stop holding back.

The problem is that cancer is adaptive. It doesn't just sit there and take the hit.

If you're looking for a specialist oncologist or general physician to discuss immunotherapy eligibility, getting the right specialist early makes a real difference.

The Two Types of Resistance

Clinicians generally split resistance into two categories: primary and acquired.

Primary resistance means the treatment never worked from day one. Acquired resistance means it worked initially, then stopped — sometimes after months, sometimes after years.

In clinical practice, this distinction is often missed because patients and families only hear "the treatment isn't working anymore" without a clear explanation of what that means for next steps. Knowing the type of resistance changes what options remain.

How Tumours Block the Immune Response

1. Hiding in Plain Sight

Cancer cells can downregulate — meaning reduce or switch off — proteins called antigens on their surface. These antigens are what T-cells use to identify cancer as a target. Without visible antigens, the immune system simply doesn't recognise the tumour as a threat.

This is one reason early cancer screening and diagnostics matter: catching cancers before they have had time to evolve stronger immune-evasion strategies can affect how well treatments work.

2. Switching Off the Kill Signal

Some tumours express alternative immune checkpoints — essentially backup brakes that weren't blocked by the original drug. If a therapy blocks one checkpoint (PD-1, for example), a cancer may activate another (like TIM-3 or LAG-3) to achieve the same result: stopping T-cells from killing it.

Researchers are now developing combination therapies targeting multiple checkpoints simultaneously, though this remains an active area of study.

3. Building a Hostile Environment

Perhaps the sneakiest mechanism. A tumour can reshape its immediate surroundings — what researchers call the tumour microenvironment — to actively suppress immune activity. It recruits cells that dampen immune responses, pumps out chemical signals that exhaust T-cells, and essentially turns its neighbourhood into a no-go zone for immune attack.

This is why consulting a specialist in oncology or immunology is important — not all resistance mechanisms respond to the same follow-up treatments.

4. Metabolic Tricks

Tumours can deplete the local environment of nutrients that T-cells need to survive. Starved of energy, immune cells in the tumour site become dysfunctional or die. It's not a well-publicised mechanism, but it's increasingly recognised as clinically significant.

Genetic Mutations: The Moving Target Problem

Cancer is not a static disease. Tumour cells mutate constantly, and under the selective pressure of immunotherapy, cells with mutations that help them escape immune attack survive and multiply — while the others are killed off.

This is essentially Darwinian evolution happening inside a person's body, compressed into months.

Patients with chronic diseases or genetic conditions that affect cell repair mechanisms may be at higher risk of rapid tumour mutation — though this varies enormously by cancer type and individual biology.

Genetic testing of tumours — liquid biopsies in particular — is becoming more common as a way to track these changes in real time. If you need diagnostic testing or pathology services near you, a referral from your oncologist is the right starting point.

Who Is Most at Risk of Resistance?

Predicting who will develop resistance remains one of oncology's harder problems. That said, certain patterns have emerged.

Tumours with lower mutational burden (fewer genetic mutations) tend to be less visible to the immune system from the start, making primary resistance more likely. High levels of a protein called PD-L1 were once thought to reliably predict response — but it's turned out to be a much messier signal than hoped.

A second opinion from an experienced oncologist before committing to a single treatment line is worth more than many patients realise.

The Role of the Gut Microbiome

This one surprises people. Research published in the last few years has shown that the composition of bacteria in your gut can influence how well immunotherapy works. Patients with more diverse gut microbiomes appear to respond better to certain checkpoint inhibitors.

Why? The gut microbiome affects systemic immune regulation — which in turn affects how aggressively T-cells respond to cancer. It's a connection that most oncology clinics are still figuring out how to act on, but it's real.

Diet, prior antibiotic use, and underlying digestive health all play into this. Seeing a gastroenterologist or a nutritionist/dietitian as part of comprehensive cancer care is increasingly recommended in integrative oncology circles.

What Happens When Resistance Develops

When acquired resistance sets in, oncologists typically reassess. Options may include switching to a different immunotherapy agent, adding targeted therapy or chemotherapy, enrolling in a clinical trial, or palliative care planning.

None of these conversations are easy. Patients experiencing emotional stress, anxiety or mental health challenges during cancer treatment should know that psychological support is part of good oncology care, not a separate concern.

If you're in Kolkata and need immediate specialist access or hospital referrals, services like Doctar make it easier to find verified oncology centres and book appointments without delays.

Combination Strategies: Fighting Resistance Head-On

The field is actively moving toward combination approaches precisely because single-agent immunotherapy so often leads to resistance. Current strategies being investigated include:

Pairing checkpoint inhibitors with drugs that remodel the tumour microenvironment. Combining immunotherapy with targeted cancer surgeries such as tumour debulking before immunotherapy initiation — reducing the cancer's ability to mount an immune escape. Using oncolytic viruses (viruses engineered to infect and kill cancer cells) to increase tumour visibility to the immune system.

These approaches are still evolving, and many are only available in clinical trials. Checking what's available through cancer hospitals near you — particularly those with research affiliations — is worthwhile.

The Mental Load of Resistance

Something that clinical literature rarely captures: the experience of being told your treatment has stopped working is psychologically devastating. Patients who had responded well often feel betrayed — by their own body, by medicine, by the hope they'd allowed themselves.

Mental health support for patients with chronic illness is not peripheral to cancer care. It's central. Oncology teams who don't address it are, frankly, not providing complete care.

If you're experiencing anxiety or depression during cancer treatment, consider speaking with a psychiatrist or counsellor who has experience in oncology settings.

Where Research Stands Right Now

The field has moved fast. CAR-T cell therapy — where a patient's own T-cells are genetically engineered to attack cancer — is already approved for some blood cancers and is being extended into solid tumours. Personalised cancer vaccines, tuned to each patient's specific tumour mutations, are in late-stage trials.

Biomarker testing is also becoming more sophisticated. Rather than relying on PD-L1 alone, oncologists are building multi-factor profiles to predict who will respond and for how long. This isn't routine yet across all hospitals, but it's coming.

For updates on technology in healthcare and medical research, Doctar's health blog covers new developments across cancer and other specialties.